The Pharmacy Times® Chronic Obstructive Pulmonary Disease (COPD) resource center provides clinical news and articles, coverage from conferences and meetings, links to condition-specific resources, and videos and other content.
What can we help you find?
At the first educational session of PQA, the speakers discussed pharmacists’ roles in influencing outcomes associated with social determinants of health in the US population.
During this period, 1834 participants developed lung cancer, of whom 290 had COPD and 1544 did not, according to the researchers.
Over $170 billion in health care spending is attributed to smoking.
As COPD progresses, patients can experience exacerbations leading to a decreased quality of life and increased costs.
Chronic obstructive pulmonary disease (COPD) leads in hospital costs, physician services, and prescription drugs.
Investigators have proposed a tool involving a personalized approach for managing chronic obstructive pulmonary disease (COPD) and the use of inhaled corticosteroids (ICS), according to the results of a recent study published in the International Journal of Chronic Obstructive Pulmonary Disease.
Continuing education for pharmacists.
The ErbB inhibitors, gefitinib, erbstatin, and tryphostin AG825, inhibit a cell signaling process controlling the death-rate of neutrophils, immune cells, which cause damage to the lungs.
High Levels of Ozone, Wood Burning Linked to Chronic Obstructive Pulmonary Disease Among Smokers, Nonsmokers
Two studies linked ozone levels and wood burning as a source of heat to an increased risk of developing chronic obstructive pulmonary disease.
The tool, which works by attaching a small sensor to the patient’s inhaler, collects data on medication use and sends medication reminders, progress reports, and disease insights to the patient’s smartphone or hub.
Each November, members of the chronic obstructive pulmonary disease (COPD) community come together to focus on increasing awareness of the respiratory condition.
Results from the safety and efficacy trial of revefenacin (REV) demonstrated that the drug had a safety profile similar to foremoterol (FOR). In addition, patients with COPD in the suboptimal peak inspiratory flow rate trial (sPIFR) showed lower weight, BMI, and lung function in comparison to patients with optimal peak inspiratory flow rate (oPIFR) in a second study.